Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab + chemotherapy + leflunomide in HER2-expressing advanced biliary tract cancer (2L)
ChiCTR2500112844Phase 2Not yet recruiting
- Sponsor
- Third Affiliated Hospital of Naval Medical University
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab and leflunomide in biliary cancer, intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma (eCCA) and 1 more, sponsored by Third Affiliated Hospital of Naval Medical University. Primary endpoint: Objective Response Rate. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
trastuzumableflunomide
03
Conditions
biliary cancerintrahepatic cholangiocarcinoma (ICC)extrahepatic cholangiocarcinoma (eCCA)gallbladder cancer
Beyond the preview
Go deeper on ChiCTR2500112844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112844.